Neuroendocrine Prostate Cancer (NEPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Neuroendocrine Prostate Cancer (NEPC) Market Outlook Thelansis’s “Neuroendocrine Prostate Cancer (NEPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuroendocrine Prostate Cancer (NEPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Neuroendocrine Prostate Cancer (NEPC) Overview Neuroendocrine prostate cancer (NEPC) is an aggressive, highly lethal variant of prostate cancer characterized by a transition from luminal adenocarcinoma to a neuroendocrine phenotype. While it can arise de novo, it most commonly develops as treatment-emergent neuroendocrine prostate cancer (t-NEPC), an adaptive resistance mechanism driven by...